New and Existing Denosumab Biosimilars Highlight the Q3 2025 Bone Metastases MarketApproval Status Updates and New Study Data Emphasized in Q3 2025 Multiple Myeloma Market

During the third quarter of 2025, the majority of pieces targeted healthcare professionals, with distribution primarily in digital form. Activity focused on multiple FDA approvals and launches of denosumab biosimilars.

Biocon Biologics announced the FDA approval of a biosimilar to Xgeva for treating skeletal-related events in patients with bone metastases and related conditions.

Henlius and Organon announced approvals from the U.S. Food and Drug Administration and the European Commission for a denosumab biosimilar to Xgeva for all reference indications.

Fresenius Kabi announced the U.S. launch of a denosumab biosimilar and, through its unbranded “More In America” campaign, showcased its leadership in oncology and biosimilars.

Celltrion announced the U.S. launch of a biosimilar to Xgeva and supported the launch with the patient support programs Celltrion Connect and Celltrion Cares, along with the “Help Along The Way” campaign.

Hikma and Richter announced the FDA approval of a denosumab biosimilar referencing Xgeva.